Nature Communications (Feb 2017)
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- Janet Lau,
- Jeanne Cheung,
- Armando Navarro,
- Steve Lianoglou,
- Benjamin Haley,
- Klara Totpal,
- Laura Sanders,
- Hartmut Koeppen,
- Patrick Caplazi,
- Jacqueline McBride,
- Henry Chiu,
- Rebecca Hong,
- Jane Grogan,
- Vincent Javinal,
- Robert Yauch,
- Bryan Irving,
- Marcia Belvin,
- Ira Mellman,
- Jeong M. Kim,
- Maike Schmidt
Affiliations
- Janet Lau
- Department of Cancer Immunology, Genentech, Inc.
- Jeanne Cheung
- Department of Cancer Immunology, Genentech, Inc.
- Armando Navarro
- Department of Translational Oncology, Genentech, Inc.
- Steve Lianoglou
- Department of Bioinformatics and Computational Biology, Genentech, Inc.
- Benjamin Haley
- Department of Molecular Biology, Genentech, Inc.
- Klara Totpal
- Department of Translational Oncology, Genentech, Inc.
- Laura Sanders
- Department of Cancer Immunology, Genentech, Inc.
- Hartmut Koeppen
- Department of Pathology, Genentech, Inc.
- Patrick Caplazi
- Department of Pathology, Genentech, Inc.
- Jacqueline McBride
- Department of Biomarker Development, Genentech, Inc.
- Henry Chiu
- Department of Biochemical and Cellular Pharmacology, Genentech, Inc.
- Rebecca Hong
- Department of Translational Oncology, Genentech, Inc.
- Jane Grogan
- Department of Cancer Immunology, Genentech, Inc.
- Vincent Javinal
- Department of Translational Oncology, Genentech, Inc.
- Robert Yauch
- Department of Discovery Oncology, Genentech, Inc. 1 DNA Way
- Bryan Irving
- Department of Cancer Immunology, Genentech, Inc.
- Marcia Belvin
- Department of Cancer Immunology, Genentech, Inc.
- Ira Mellman
- Department of Cancer Immunology, Genentech, Inc.
- Jeong M. Kim
- Department of Cancer Immunology, Genentech, Inc.
- Maike Schmidt
- Department of Cancer Immunology, Genentech, Inc.
- DOI
- https://doi.org/10.1038/ncomms14572
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 11
Abstract
PD-L1, the ligand for T-cell inhibitory receptor PD-1, can be expressed by various cell types in the tumour microenvironment. Here, the authors show that, in mouse models, the expression of PD-L1 from both cancerous and normal host immune cells is important for suppressing anti-tumour immune responses.
